JP2023174661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023174661A5 JP2023174661A5 JP2023150724A JP2023150724A JP2023174661A5 JP 2023174661 A5 JP2023174661 A5 JP 2023174661A5 JP 2023150724 A JP2023150724 A JP 2023150724A JP 2023150724 A JP2023150724 A JP 2023150724A JP 2023174661 A5 JP2023174661 A5 JP 2023174661A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- posaconazole
- encorafenib
- discontinuing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025098467A JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/596,585 US10376507B2 (en) | 2017-05-16 | 2017-05-16 | Method of treating a patient with a CYP3A4 substrate drug |
| US16/036,678 US20180333411A1 (en) | 2017-05-16 | 2018-07-16 | Methods of treatment |
| US16/036,678 | 2018-07-16 | ||
| JP2020536002A JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| PCT/US2018/061141 WO2020018136A1 (en) | 2017-05-16 | 2018-11-14 | Methods of treatment with cyp3a4 substrate drugs |
| JP2021189815A JP7353343B2 (ja) | 2017-05-16 | 2021-11-24 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189815A Division JP7353343B2 (ja) | 2017-05-16 | 2021-11-24 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025098467A Division JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023174661A JP2023174661A (ja) | 2023-12-08 |
| JP2023174661A5 true JP2023174661A5 (https=) | 2024-08-07 |
| JP7698009B2 JP7698009B2 (ja) | 2025-06-24 |
Family
ID=64269934
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572833A Pending JP2020520380A (ja) | 2017-05-16 | 2017-05-16 | 処置法 |
| JP2020536002A Active JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2021008114A Pending JP2021059610A (ja) | 2017-05-16 | 2021-01-21 | 処置法 |
| JP2021189815A Active JP7353343B2 (ja) | 2017-05-16 | 2021-11-24 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2022198263A Pending JP2023021260A (ja) | 2017-05-16 | 2022-12-12 | 処置法 |
| JP2023150724A Active JP7698009B2 (ja) | 2017-05-16 | 2023-09-19 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2025098467A Pending JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572833A Pending JP2020520380A (ja) | 2017-05-16 | 2017-05-16 | 処置法 |
| JP2020536002A Active JP6984024B2 (ja) | 2017-05-16 | 2018-11-14 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2021008114A Pending JP2021059610A (ja) | 2017-05-16 | 2021-01-21 | 処置法 |
| JP2021189815A Active JP7353343B2 (ja) | 2017-05-16 | 2021-11-24 | Ｃｙｐ３ａ４基質薬物による処置方法 |
| JP2022198263A Pending JP2023021260A (ja) | 2017-05-16 | 2022-12-12 | 処置法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025098467A Pending JP2025137510A (ja) | 2017-05-16 | 2025-06-12 | Ｃｙｐ３ａ４基質薬物による処置方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US10376507B2 (https=) |
| EP (4) | EP4082546A1 (https=) |
| JP (7) | JP2020520380A (https=) |
| KR (3) | KR20200010320A (https=) |
| AU (11) | AU2017414697B2 (https=) |
| CA (1) | CA3103793A1 (https=) |
| DK (2) | DK3426250T3 (https=) |
| ES (2) | ES2912373T3 (https=) |
| FI (1) | FI3716976T3 (https=) |
| HR (1) | HRP20220536T1 (https=) |
| MX (4) | MX2019013714A (https=) |
| PL (1) | PL3426250T3 (https=) |
| SI (1) | SI3426250T1 (https=) |
| WO (2) | WO2018212764A1 (https=) |
| ZA (1) | ZA202006746B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108925135B (zh) | 2015-12-23 | 2025-09-19 | 纽罗克里生物科学有限公司 | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| JP2020520380A (ja) | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| US20220143011A1 (en) | 2017-05-16 | 2022-05-12 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
| US11110098B2 (en) * | 2017-06-07 | 2021-09-07 | University Of Kansas | Methods and medicaments for the treatment of renal cell carcinoma |
| ES3024958T3 (en) | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CN109966298A (zh) * | 2019-05-10 | 2019-07-05 | 辽宁大学 | 托伐普坦在制备降血脂药物中的应用 |
| WO2020247366A1 (en) * | 2019-06-05 | 2020-12-10 | University Of Georgia Research Foundation | Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| US12168005B2 (en) | 2019-10-07 | 2024-12-17 | University Hospitals Cleveland Medical Center | Methods for treating wild type isocitrate dehydrogenase 1 cancers |
| WO2021095532A1 (ja) * | 2019-11-15 | 2021-05-20 | 株式会社カルディオインテリジェンス | 医薬品の用法及び用量の少なくとも一方の決定を支援するための方法、プログラム、装置及びシステム |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| TWI865760B (zh) * | 2020-04-01 | 2024-12-11 | 日商大塚製藥股份有限公司 | 阿立哌唑注射用製劑之投予方法 |
| US12605387B2 (en) | 2020-07-24 | 2026-04-21 | Secura Bio, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| KR102601028B1 (ko) | 2020-08-18 | 2023-11-10 | 재단법인대구경북과학기술원 | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| EP4201406A4 (en) * | 2020-08-18 | 2024-08-28 | Daegu Gyeongbuk Institute Of Science and Technology | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES COMPRISING ABEMACICLIB AS ACTIVE INGREDIENT |
| CN111920814B (zh) * | 2020-09-04 | 2022-02-11 | 郑州大学 | 依匹哌唑在制备抗肿瘤药物中的应用 |
| CN112898131B (zh) * | 2020-11-05 | 2023-08-22 | 苏州凯祥生物科技有限公司 | 大麻二酚的提取工艺及大麻二酚或大麻提取物在制备预防或者治疗bph的药物中的应用 |
| CN112206297B (zh) * | 2020-11-16 | 2022-01-11 | 深圳市宝安区人民医院 | 治疗心脾两虚型失眠症的中药制剂及其制备方法 |
| US11229644B1 (en) | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| JP2024502431A (ja) * | 2020-12-31 | 2024-01-19 | レイク オハラ エルエルシー | 肥満患者における、ブレクスピプラゾールを用いた精神疾患の治療方法 |
| CN112675175B (zh) * | 2021-02-01 | 2022-11-01 | 天津济坤医药科技有限公司 | 布里格替尼在制备治疗特发性肺纤维化的药物中的应用 |
| WO2023101441A1 (ko) * | 2021-11-30 | 2023-06-08 | 에스케이케미칼 주식회사 | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 |
| WO2023141634A2 (en) * | 2022-01-24 | 2023-07-27 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| US20250302821A1 (en) * | 2022-05-12 | 2025-10-02 | St. Jude Children's Research Hospital, Inc. | Synergistic antifungal composition and method |
| CN117045643A (zh) * | 2023-09-26 | 2023-11-14 | 江苏百奥信康医药科技有限公司 | 一种cftr矫正剂在制备治疗乳腺增生症的药物中的应用 |
| CN117257994B (zh) * | 2023-11-21 | 2024-03-01 | 北京大学人民医院 | 动物模型的构建方法及应用 |
| CN121513027A (zh) * | 2026-01-15 | 2026-02-13 | 浙江大学 | 核苷类化合物在制备治疗神经肌肉疾病药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973970B2 (en) * | 2000-08-09 | 2011-07-05 | Ether Visuals Llc | Preventing artifacts that may be produced when bottling PDL files converted from raster images |
| EP2023923A2 (en) | 2006-05-25 | 2009-02-18 | Bristol-Myers Squibb Company | Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals |
| US7820681B1 (en) * | 2009-01-14 | 2010-10-26 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
| US7816383B1 (en) * | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| DK3223796T3 (da) | 2014-11-25 | 2021-09-27 | Curadigm Sas | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf |
| US10493024B2 (en) | 2015-10-12 | 2019-12-03 | Hk Tumescent Pharma Corporation | Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| JP2019533692A (ja) | 2016-11-09 | 2019-11-21 | サインパス ファルマ, インク.Signpath Pharma, Inc. | チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防護効果 |
| JP2020520380A (ja) * | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
-
2017
- 2017-05-16 JP JP2019572833A patent/JP2020520380A/ja active Pending
- 2017-05-16 WO PCT/US2017/032924 patent/WO2018212764A1/en not_active Ceased
- 2017-05-16 KR KR1020197036786A patent/KR20200010320A/ko not_active Ceased
- 2017-05-16 ES ES17897227T patent/ES2912373T3/es active Active
- 2017-05-16 SI SI201731136T patent/SI3426250T1/sl unknown
- 2017-05-16 PL PL17897227.9T patent/PL3426250T3/pl unknown
- 2017-05-16 DK DK17897227.9T patent/DK3426250T3/da active
- 2017-05-16 US US15/596,585 patent/US10376507B2/en active Active
- 2017-05-16 EP EP22163202.9A patent/EP4082546A1/en not_active Withdrawn
- 2017-05-16 HR HRP20220536TT patent/HRP20220536T1/hr unknown
- 2017-05-16 KR KR1020217001925A patent/KR20210010663A/ko not_active Ceased
- 2017-05-16 MX MX2019013714A patent/MX2019013714A/es unknown
- 2017-05-16 AU AU2017414697A patent/AU2017414697B2/en active Active
- 2017-05-16 EP EP17897227.9A patent/EP3426250B1/en active Active
- 2017-08-07 US US15/670,271 patent/US20180333410A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/036,678 patent/US20180333411A1/en not_active Abandoned
- 2018-11-14 US US16/191,351 patent/US10835529B2/en active Active
- 2018-11-14 AU AU2018432858A patent/AU2018432858B2/en active Active
- 2018-11-14 KR KR1020217004371A patent/KR102805232B1/ko active Active
- 2018-11-14 EP EP24193158.3A patent/EP4461298A3/en active Pending
- 2018-11-14 CA CA3103793A patent/CA3103793A1/en active Pending
- 2018-11-14 JP JP2020536002A patent/JP6984024B2/ja active Active
- 2018-11-14 ES ES18926463T patent/ES2993832T3/es active Active
- 2018-11-14 WO PCT/US2018/061141 patent/WO2020018136A1/en not_active Ceased
- 2018-11-14 MX MX2021000609A patent/MX2021000609A/es unknown
- 2018-11-14 FI FIEP18926463.3T patent/FI3716976T3/fi active
- 2018-11-14 EP EP18926463.3A patent/EP3716976B1/en active Active
- 2018-11-14 DK DK18926463.3T patent/DK3716976T3/da active
-
2019
- 2019-03-12 US US16/351,198 patent/US20190255043A1/en not_active Abandoned
- 2019-11-15 MX MX2022013410A patent/MX2022013410A/es unknown
-
2020
- 2020-03-24 AU AU2020202100A patent/AU2020202100B2/en active Active
- 2020-03-30 AU AU2020202266A patent/AU2020202266B2/en active Active
- 2020-06-02 AU AU2020203608A patent/AU2020203608B2/en active Active
- 2020-06-02 AU AU2020203607A patent/AU2020203607B2/en active Active
- 2020-06-02 AU AU2020203606A patent/AU2020203606B2/en active Active
- 2020-10-08 AU AU2020250281A patent/AU2020250281B2/en active Active
- 2020-10-29 ZA ZA2020/06746A patent/ZA202006746B/en unknown
- 2020-11-16 US US17/099,298 patent/US11123346B2/en active Active
-
2021
- 2021-01-15 MX MX2025000380A patent/MX2025000380A/es unknown
- 2021-01-21 JP JP2021008114A patent/JP2021059610A/ja active Pending
- 2021-11-24 JP JP2021189815A patent/JP7353343B2/ja active Active
-
2022
- 2022-07-05 AU AU2022204806A patent/AU2022204806B2/en active Active
- 2022-09-08 AU AU2022228153A patent/AU2022228153B2/en not_active Expired - Fee Related
- 2022-12-12 JP JP2022198263A patent/JP2023021260A/ja active Pending
-
2023
- 2023-09-19 JP JP2023150724A patent/JP7698009B2/ja active Active
-
2025
- 2025-06-12 JP JP2025098467A patent/JP2025137510A/ja active Pending
- 2025-12-24 AU AU2025287373A patent/AU2025287373A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023174661A5 (https=) | ||
| JP2022022264A5 (https=) | ||
| CN111012784B (zh) | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 | |
| JP2021534129A5 (https=) | ||
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| EA024186B1 (ru) | Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты | |
| JP2020505425A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| JPWO2022269525A5 (https=) | ||
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| JP2016094450A (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| AU2021272100A1 (en) | Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JPWO2020229626A5 (https=) | ||
| JPWO2022200982A5 (https=) | ||
| CN106038566B (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
| Cortes et al. | CML-387 ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results | |
| JPWO2021224867A5 (https=) | ||
| JPWO2021262562A5 (https=) | ||
| JPWO2021262563A5 (https=) | ||
| Wu et al. | EP08. 02-157 Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/MRK Inhibition in BRAF V600Emutant NSCLC | |
| JPWO2020165181A5 (https=) | ||
| CN101530414B (zh) | 化合物酮色林的应用 | |
| HK40059774A (en) | Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer | |
| CN115364228A (zh) | 一种治疗卵巢癌的药物组合 |